Global Non-Insulin Hypoglycemic Drug Market Growth 2022-2028
The report requires updating with new data and is sent in 48 hours after order is placed.
The global market for Non-Insulin Hypoglycemic Drug is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC Non-Insulin Hypoglycemic Drug market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States Non-Insulin Hypoglycemic Drug market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe Non-Insulin Hypoglycemic Drug market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China Non-Insulin Hypoglycemic Drug market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key Non-Insulin Hypoglycemic Drug players cover GSK, Eli Lilly, Sumitomo Dainippon Pharma, Intarcia Therapeutics and Servier, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
Report Coverage
This latest report provides a deep insight into the global Non-Insulin Hypoglycemic Drug market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global Non-Insulin Hypoglycemic Drug market, with both quantitative and qualitative data, to help readers understand how the Non-Insulin Hypoglycemic Drug market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in K Units.
Market Segmentation:
The study segments the Non-Insulin Hypoglycemic Drug market and forecasts the market size by Type (Sulfonylureas, Meglitinides and Biguanides), by Application (Hospital Pharmacies and Retail Pharmacies.), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
Chapter 1: Scope of Non-Insulin Hypoglycemic Drug, Research Methodology, etc.
Chapter 2: Executive Summary, global Non-Insulin Hypoglycemic Drug market size (sales and revenue) and CAGR, Non-Insulin Hypoglycemic Drug market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Non-Insulin Hypoglycemic Drug sales, revenue, average price, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Non-Insulin Hypoglycemic Drug sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Non-Insulin Hypoglycemic Drug market size forecast by region, by country, by type, and application.
Chapter 13: Comprehensive company profiles of the leading players, including GSK, Eli Lilly, Sumitomo Dainippon Pharma, Intarcia Therapeutics, Servier, Pfizer, Merck, Dong-A Pharmaceutical and Luye Pharma Group, etc.
Chapter 14: Research Findings and Conclusion
The global market for Non-Insulin Hypoglycemic Drug is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC Non-Insulin Hypoglycemic Drug market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States Non-Insulin Hypoglycemic Drug market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe Non-Insulin Hypoglycemic Drug market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China Non-Insulin Hypoglycemic Drug market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key Non-Insulin Hypoglycemic Drug players cover GSK, Eli Lilly, Sumitomo Dainippon Pharma, Intarcia Therapeutics and Servier, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
Report Coverage
This latest report provides a deep insight into the global Non-Insulin Hypoglycemic Drug market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global Non-Insulin Hypoglycemic Drug market, with both quantitative and qualitative data, to help readers understand how the Non-Insulin Hypoglycemic Drug market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in K Units.
Market Segmentation:
The study segments the Non-Insulin Hypoglycemic Drug market and forecasts the market size by Type (Sulfonylureas, Meglitinides and Biguanides), by Application (Hospital Pharmacies and Retail Pharmacies.), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
- Sulfonylureas
- Meglitinides
- Biguanides
- Thiazolidinediones
- Alpha Glucosidase Inhibitors
- Others
- Hospital Pharmacies
- Retail Pharmacies
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- GSK
- Eli Lilly
- Sumitomo Dainippon Pharma
- Intarcia Therapeutics
- Servier
- Pfizer
- Merck
- Dong-A Pharmaceutical
- Luye Pharma Group
- Eurofarma
- Geropharm
- Alkem Labs
- Jiangsu Hansoh Pharmaceutical
- Novo Nordisk
- Emisphere
- Uni-Bio Science Group
- Takeda
- 3SBio
- Jiangsu Hengrui Medicine
Chapter 1: Scope of Non-Insulin Hypoglycemic Drug, Research Methodology, etc.
Chapter 2: Executive Summary, global Non-Insulin Hypoglycemic Drug market size (sales and revenue) and CAGR, Non-Insulin Hypoglycemic Drug market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Non-Insulin Hypoglycemic Drug sales, revenue, average price, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Non-Insulin Hypoglycemic Drug sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Non-Insulin Hypoglycemic Drug market size forecast by region, by country, by type, and application.
Chapter 13: Comprehensive company profiles of the leading players, including GSK, Eli Lilly, Sumitomo Dainippon Pharma, Intarcia Therapeutics, Servier, Pfizer, Merck, Dong-A Pharmaceutical and Luye Pharma Group, etc.
Chapter 14: Research Findings and Conclusion
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Non-Insulin Hypoglycemic Drug Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Non-Insulin Hypoglycemic Drug by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Non-Insulin Hypoglycemic Drug by Country/Region, 2017, 2022 & 2028
2.2 Non-Insulin Hypoglycemic Drug Segment by Type
2.2.1 Sulfonylureas
2.2.2 Meglitinides
2.2.3 Biguanides
2.2.4 Thiazolidinediones
2.2.5 Alpha Glucosidase Inhibitors
2.2.6 Others
2.3 Non-Insulin Hypoglycemic Drug Sales by Type
2.3.1 Global Non-Insulin Hypoglycemic Drug Sales Market Share by Type (2017-2022)
2.3.2 Global Non-Insulin Hypoglycemic Drug Revenue and Market Share by Type (2017-2022)
2.3.3 Global Non-Insulin Hypoglycemic Drug Sale Price by Type (2017-2022)
2.4 Non-Insulin Hypoglycemic Drug Segment by Application
2.4.1 Hospital Pharmacies
2.4.2 Retail Pharmacies
2.5 Non-Insulin Hypoglycemic Drug Sales by Application
2.5.1 Global Non-Insulin Hypoglycemic Drug Sale Market Share by Application (2017-2022)
2.5.2 Global Non-Insulin Hypoglycemic Drug Revenue and Market Share by Application (2017-2022)
2.5.3 Global Non-Insulin Hypoglycemic Drug Sale Price by Application (2017-2022)
3 GLOBAL NON-INSULIN HYPOGLYCEMIC DRUG BY COMPANY
3.1 Global Non-Insulin Hypoglycemic Drug Breakdown Data by Company
3.1.1 Global Non-Insulin Hypoglycemic Drug Annual Sales by Company (2020-2022)
3.1.2 Global Non-Insulin Hypoglycemic Drug Sales Market Share by Company (2020-2022)
3.2 Global Non-Insulin Hypoglycemic Drug Annual Revenue by Company (2020-2022)
3.2.1 Global Non-Insulin Hypoglycemic Drug Revenue by Company (2020-2022)
3.2.2 Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Company (2020-2022)
3.3 Global Non-Insulin Hypoglycemic Drug Sale Price by Company
3.4 Key Manufacturers Non-Insulin Hypoglycemic Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Non-Insulin Hypoglycemic Drug Product Location Distribution
3.4.2 Players Non-Insulin Hypoglycemic Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR NON-INSULIN HYPOGLYCEMIC DRUG BY GEOGRAPHIC REGION
4.1 World Historic Non-Insulin Hypoglycemic Drug Market Size by Geographic Region (2017-2022)
4.1.1 Global Non-Insulin Hypoglycemic Drug Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Non-Insulin Hypoglycemic Drug Annual Revenue by Geographic Region
4.2 World Historic Non-Insulin Hypoglycemic Drug Market Size by Country/Region (2017-2022)
4.2.1 Global Non-Insulin Hypoglycemic Drug Annual Sales by Country/Region (2017-2022)
4.2.2 Global Non-Insulin Hypoglycemic Drug Annual Revenue by Country/Region
4.3 Americas Non-Insulin Hypoglycemic Drug Sales Growth
4.4 APAC Non-Insulin Hypoglycemic Drug Sales Growth
4.5 Europe Non-Insulin Hypoglycemic Drug Sales Growth
4.6 Middle East & Africa Non-Insulin Hypoglycemic Drug Sales Growth
5 AMERICAS
5.1 Americas Non-Insulin Hypoglycemic Drug Sales by Country
5.1.1 Americas Non-Insulin Hypoglycemic Drug Sales by Country (2017-2022)
5.1.2 Americas Non-Insulin Hypoglycemic Drug Revenue by Country (2017-2022)
5.2 Americas Non-Insulin Hypoglycemic Drug Sales by Type
5.3 Americas Non-Insulin Hypoglycemic Drug Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Non-Insulin Hypoglycemic Drug Sales by Region
6.1.1 APAC Non-Insulin Hypoglycemic Drug Sales by Region (2017-2022)
6.1.2 APAC Non-Insulin Hypoglycemic Drug Revenue by Region (2017-2022)
6.2 APAC Non-Insulin Hypoglycemic Drug Sales by Type
6.3 APAC Non-Insulin Hypoglycemic Drug Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Non-Insulin Hypoglycemic Drug by Country
7.1.1 Europe Non-Insulin Hypoglycemic Drug Sales by Country (2017-2022)
7.1.2 Europe Non-Insulin Hypoglycemic Drug Revenue by Country (2017-2022)
7.2 Europe Non-Insulin Hypoglycemic Drug Sales by Type
7.3 Europe Non-Insulin Hypoglycemic Drug Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Non-Insulin Hypoglycemic Drug by Country
8.1.1 Middle East & Africa Non-Insulin Hypoglycemic Drug Sales by Country (2017-2022)
8.1.2 Middle East & Africa Non-Insulin Hypoglycemic Drug Revenue by Country (2017-2022)
8.2 Middle East & Africa Non-Insulin Hypoglycemic Drug Sales by Type
8.3 Middle East & Africa Non-Insulin Hypoglycemic Drug Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Non-Insulin Hypoglycemic Drug
10.3 Manufacturing Process Analysis of Non-Insulin Hypoglycemic Drug
10.4 Industry Chain Structure of Non-Insulin Hypoglycemic Drug
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Non-Insulin Hypoglycemic Drug Distributors
11.3 Non-Insulin Hypoglycemic Drug Customer
12 WORLD FORECAST REVIEW FOR NON-INSULIN HYPOGLYCEMIC DRUG BY GEOGRAPHIC REGION
12.1 Global Non-Insulin Hypoglycemic Drug Market Size Forecast by Region
12.1.1 Global Non-Insulin Hypoglycemic Drug Forecast by Region (2023-2028)
12.1.2 Global Non-Insulin Hypoglycemic Drug Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Non-Insulin Hypoglycemic Drug Forecast by Type
12.7 Global Non-Insulin Hypoglycemic Drug Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 GSK
13.1.1 GSK Company Information
13.1.2 GSK Non-Insulin Hypoglycemic Drug Product Offered
13.1.3 GSK Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 GSK Main Business Overview
13.1.5 GSK Latest Developments
13.2 Eli Lilly
13.2.1 Eli Lilly Company Information
13.2.2 Eli Lilly Non-Insulin Hypoglycemic Drug Product Offered
13.2.3 Eli Lilly Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 Eli Lilly Main Business Overview
13.2.5 Eli Lilly Latest Developments
13.3 Sumitomo Dainippon Pharma
13.3.1 Sumitomo Dainippon Pharma Company Information
13.3.2 Sumitomo Dainippon Pharma Non-Insulin Hypoglycemic Drug Product Offered
13.3.3 Sumitomo Dainippon Pharma Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 Sumitomo Dainippon Pharma Main Business Overview
13.3.5 Sumitomo Dainippon Pharma Latest Developments
13.4 Intarcia Therapeutics
13.4.1 Intarcia Therapeutics Company Information
13.4.2 Intarcia Therapeutics Non-Insulin Hypoglycemic Drug Product Offered
13.4.3 Intarcia Therapeutics Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 Intarcia Therapeutics Main Business Overview
13.4.5 Intarcia Therapeutics Latest Developments
13.5 Servier
13.5.1 Servier Company Information
13.5.2 Servier Non-Insulin Hypoglycemic Drug Product Offered
13.5.3 Servier Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 Servier Main Business Overview
13.5.5 Servier Latest Developments
13.6 Pfizer
13.6.1 Pfizer Company Information
13.6.2 Pfizer Non-Insulin Hypoglycemic Drug Product Offered
13.6.3 Pfizer Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 Pfizer Main Business Overview
13.6.5 Pfizer Latest Developments
13.7 Merck
13.7.1 Merck Company Information
13.7.2 Merck Non-Insulin Hypoglycemic Drug Product Offered
13.7.3 Merck Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 Merck Main Business Overview
13.7.5 Merck Latest Developments
13.8 Dong-A Pharmaceutical
13.8.1 Dong-A Pharmaceutical Company Information
13.8.2 Dong-A Pharmaceutical Non-Insulin Hypoglycemic Drug Product Offered
13.8.3 Dong-A Pharmaceutical Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.8.4 Dong-A Pharmaceutical Main Business Overview
13.8.5 Dong-A Pharmaceutical Latest Developments
13.9 Luye Pharma Group
13.9.1 Luye Pharma Group Company Information
13.9.2 Luye Pharma Group Non-Insulin Hypoglycemic Drug Product Offered
13.9.3 Luye Pharma Group Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.9.4 Luye Pharma Group Main Business Overview
13.9.5 Luye Pharma Group Latest Developments
13.10 Eurofarma
13.10.1 Eurofarma Company Information
13.10.2 Eurofarma Non-Insulin Hypoglycemic Drug Product Offered
13.10.3 Eurofarma Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.10.4 Eurofarma Main Business Overview
13.10.5 Eurofarma Latest Developments
13.11 Geropharm
13.11.1 Geropharm Company Information
13.11.2 Geropharm Non-Insulin Hypoglycemic Drug Product Offered
13.11.3 Geropharm Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.11.4 Geropharm Main Business Overview
13.11.5 Geropharm Latest Developments
13.12 Alkem Labs
13.12.1 Alkem Labs Company Information
13.12.2 Alkem Labs Non-Insulin Hypoglycemic Drug Product Offered
13.12.3 Alkem Labs Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.12.4 Alkem Labs Main Business Overview
13.12.5 Alkem Labs Latest Developments
13.13 Jiangsu Hansoh Pharmaceutical
13.13.1 Jiangsu Hansoh Pharmaceutical Company Information
13.13.2 Jiangsu Hansoh Pharmaceutical Non-Insulin Hypoglycemic Drug Product Offered
13.13.3 Jiangsu Hansoh Pharmaceutical Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.13.4 Jiangsu Hansoh Pharmaceutical Main Business Overview
13.13.5 Jiangsu Hansoh Pharmaceutical Latest Developments
13.14 Novo Nordisk
13.14.1 Novo Nordisk Company Information
13.14.2 Novo Nordisk Non-Insulin Hypoglycemic Drug Product Offered
13.14.3 Novo Nordisk Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.14.4 Novo Nordisk Main Business Overview
13.14.5 Novo Nordisk Latest Developments
13.15 Emisphere
13.15.1 Emisphere Company Information
13.15.2 Emisphere Non-Insulin Hypoglycemic Drug Product Offered
13.15.3 Emisphere Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.15.4 Emisphere Main Business Overview
13.15.5 Emisphere Latest Developments
13.16 Uni-Bio Science Group
13.16.1 Uni-Bio Science Group Company Information
13.16.2 Uni-Bio Science Group Non-Insulin Hypoglycemic Drug Product Offered
13.16.3 Uni-Bio Science Group Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.16.4 Uni-Bio Science Group Main Business Overview
13.16.5 Uni-Bio Science Group Latest Developments
13.17 Takeda
13.17.1 Takeda Company Information
13.17.2 Takeda Non-Insulin Hypoglycemic Drug Product Offered
13.17.3 Takeda Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.17.4 Takeda Main Business Overview
13.17.5 Takeda Latest Developments
13.18 3SBio
13.18.1 3SBio Company Information
13.18.2 3SBio Non-Insulin Hypoglycemic Drug Product Offered
13.18.3 3SBio Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.18.4 3SBio Main Business Overview
13.18.5 3SBio Latest Developments
13.19 Jiangsu Hengrui Medicine
13.19.1 Jiangsu Hengrui Medicine Company Information
13.19.2 Jiangsu Hengrui Medicine Non-Insulin Hypoglycemic Drug Product Offered
13.19.3 Jiangsu Hengrui Medicine Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.19.4 Jiangsu Hengrui Medicine Main Business Overview
13.19.5 Jiangsu Hengrui Medicine Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Non-Insulin Hypoglycemic Drug Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Non-Insulin Hypoglycemic Drug by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Non-Insulin Hypoglycemic Drug by Country/Region, 2017, 2022 & 2028
2.2 Non-Insulin Hypoglycemic Drug Segment by Type
2.2.1 Sulfonylureas
2.2.2 Meglitinides
2.2.3 Biguanides
2.2.4 Thiazolidinediones
2.2.5 Alpha Glucosidase Inhibitors
2.2.6 Others
2.3 Non-Insulin Hypoglycemic Drug Sales by Type
2.3.1 Global Non-Insulin Hypoglycemic Drug Sales Market Share by Type (2017-2022)
2.3.2 Global Non-Insulin Hypoglycemic Drug Revenue and Market Share by Type (2017-2022)
2.3.3 Global Non-Insulin Hypoglycemic Drug Sale Price by Type (2017-2022)
2.4 Non-Insulin Hypoglycemic Drug Segment by Application
2.4.1 Hospital Pharmacies
2.4.2 Retail Pharmacies
2.5 Non-Insulin Hypoglycemic Drug Sales by Application
2.5.1 Global Non-Insulin Hypoglycemic Drug Sale Market Share by Application (2017-2022)
2.5.2 Global Non-Insulin Hypoglycemic Drug Revenue and Market Share by Application (2017-2022)
2.5.3 Global Non-Insulin Hypoglycemic Drug Sale Price by Application (2017-2022)
3 GLOBAL NON-INSULIN HYPOGLYCEMIC DRUG BY COMPANY
3.1 Global Non-Insulin Hypoglycemic Drug Breakdown Data by Company
3.1.1 Global Non-Insulin Hypoglycemic Drug Annual Sales by Company (2020-2022)
3.1.2 Global Non-Insulin Hypoglycemic Drug Sales Market Share by Company (2020-2022)
3.2 Global Non-Insulin Hypoglycemic Drug Annual Revenue by Company (2020-2022)
3.2.1 Global Non-Insulin Hypoglycemic Drug Revenue by Company (2020-2022)
3.2.2 Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Company (2020-2022)
3.3 Global Non-Insulin Hypoglycemic Drug Sale Price by Company
3.4 Key Manufacturers Non-Insulin Hypoglycemic Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Non-Insulin Hypoglycemic Drug Product Location Distribution
3.4.2 Players Non-Insulin Hypoglycemic Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR NON-INSULIN HYPOGLYCEMIC DRUG BY GEOGRAPHIC REGION
4.1 World Historic Non-Insulin Hypoglycemic Drug Market Size by Geographic Region (2017-2022)
4.1.1 Global Non-Insulin Hypoglycemic Drug Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Non-Insulin Hypoglycemic Drug Annual Revenue by Geographic Region
4.2 World Historic Non-Insulin Hypoglycemic Drug Market Size by Country/Region (2017-2022)
4.2.1 Global Non-Insulin Hypoglycemic Drug Annual Sales by Country/Region (2017-2022)
4.2.2 Global Non-Insulin Hypoglycemic Drug Annual Revenue by Country/Region
4.3 Americas Non-Insulin Hypoglycemic Drug Sales Growth
4.4 APAC Non-Insulin Hypoglycemic Drug Sales Growth
4.5 Europe Non-Insulin Hypoglycemic Drug Sales Growth
4.6 Middle East & Africa Non-Insulin Hypoglycemic Drug Sales Growth
5 AMERICAS
5.1 Americas Non-Insulin Hypoglycemic Drug Sales by Country
5.1.1 Americas Non-Insulin Hypoglycemic Drug Sales by Country (2017-2022)
5.1.2 Americas Non-Insulin Hypoglycemic Drug Revenue by Country (2017-2022)
5.2 Americas Non-Insulin Hypoglycemic Drug Sales by Type
5.3 Americas Non-Insulin Hypoglycemic Drug Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Non-Insulin Hypoglycemic Drug Sales by Region
6.1.1 APAC Non-Insulin Hypoglycemic Drug Sales by Region (2017-2022)
6.1.2 APAC Non-Insulin Hypoglycemic Drug Revenue by Region (2017-2022)
6.2 APAC Non-Insulin Hypoglycemic Drug Sales by Type
6.3 APAC Non-Insulin Hypoglycemic Drug Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Non-Insulin Hypoglycemic Drug by Country
7.1.1 Europe Non-Insulin Hypoglycemic Drug Sales by Country (2017-2022)
7.1.2 Europe Non-Insulin Hypoglycemic Drug Revenue by Country (2017-2022)
7.2 Europe Non-Insulin Hypoglycemic Drug Sales by Type
7.3 Europe Non-Insulin Hypoglycemic Drug Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Non-Insulin Hypoglycemic Drug by Country
8.1.1 Middle East & Africa Non-Insulin Hypoglycemic Drug Sales by Country (2017-2022)
8.1.2 Middle East & Africa Non-Insulin Hypoglycemic Drug Revenue by Country (2017-2022)
8.2 Middle East & Africa Non-Insulin Hypoglycemic Drug Sales by Type
8.3 Middle East & Africa Non-Insulin Hypoglycemic Drug Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Non-Insulin Hypoglycemic Drug
10.3 Manufacturing Process Analysis of Non-Insulin Hypoglycemic Drug
10.4 Industry Chain Structure of Non-Insulin Hypoglycemic Drug
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Non-Insulin Hypoglycemic Drug Distributors
11.3 Non-Insulin Hypoglycemic Drug Customer
12 WORLD FORECAST REVIEW FOR NON-INSULIN HYPOGLYCEMIC DRUG BY GEOGRAPHIC REGION
12.1 Global Non-Insulin Hypoglycemic Drug Market Size Forecast by Region
12.1.1 Global Non-Insulin Hypoglycemic Drug Forecast by Region (2023-2028)
12.1.2 Global Non-Insulin Hypoglycemic Drug Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Non-Insulin Hypoglycemic Drug Forecast by Type
12.7 Global Non-Insulin Hypoglycemic Drug Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 GSK
13.1.1 GSK Company Information
13.1.2 GSK Non-Insulin Hypoglycemic Drug Product Offered
13.1.3 GSK Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 GSK Main Business Overview
13.1.5 GSK Latest Developments
13.2 Eli Lilly
13.2.1 Eli Lilly Company Information
13.2.2 Eli Lilly Non-Insulin Hypoglycemic Drug Product Offered
13.2.3 Eli Lilly Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 Eli Lilly Main Business Overview
13.2.5 Eli Lilly Latest Developments
13.3 Sumitomo Dainippon Pharma
13.3.1 Sumitomo Dainippon Pharma Company Information
13.3.2 Sumitomo Dainippon Pharma Non-Insulin Hypoglycemic Drug Product Offered
13.3.3 Sumitomo Dainippon Pharma Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 Sumitomo Dainippon Pharma Main Business Overview
13.3.5 Sumitomo Dainippon Pharma Latest Developments
13.4 Intarcia Therapeutics
13.4.1 Intarcia Therapeutics Company Information
13.4.2 Intarcia Therapeutics Non-Insulin Hypoglycemic Drug Product Offered
13.4.3 Intarcia Therapeutics Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 Intarcia Therapeutics Main Business Overview
13.4.5 Intarcia Therapeutics Latest Developments
13.5 Servier
13.5.1 Servier Company Information
13.5.2 Servier Non-Insulin Hypoglycemic Drug Product Offered
13.5.3 Servier Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 Servier Main Business Overview
13.5.5 Servier Latest Developments
13.6 Pfizer
13.6.1 Pfizer Company Information
13.6.2 Pfizer Non-Insulin Hypoglycemic Drug Product Offered
13.6.3 Pfizer Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 Pfizer Main Business Overview
13.6.5 Pfizer Latest Developments
13.7 Merck
13.7.1 Merck Company Information
13.7.2 Merck Non-Insulin Hypoglycemic Drug Product Offered
13.7.3 Merck Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 Merck Main Business Overview
13.7.5 Merck Latest Developments
13.8 Dong-A Pharmaceutical
13.8.1 Dong-A Pharmaceutical Company Information
13.8.2 Dong-A Pharmaceutical Non-Insulin Hypoglycemic Drug Product Offered
13.8.3 Dong-A Pharmaceutical Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.8.4 Dong-A Pharmaceutical Main Business Overview
13.8.5 Dong-A Pharmaceutical Latest Developments
13.9 Luye Pharma Group
13.9.1 Luye Pharma Group Company Information
13.9.2 Luye Pharma Group Non-Insulin Hypoglycemic Drug Product Offered
13.9.3 Luye Pharma Group Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.9.4 Luye Pharma Group Main Business Overview
13.9.5 Luye Pharma Group Latest Developments
13.10 Eurofarma
13.10.1 Eurofarma Company Information
13.10.2 Eurofarma Non-Insulin Hypoglycemic Drug Product Offered
13.10.3 Eurofarma Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.10.4 Eurofarma Main Business Overview
13.10.5 Eurofarma Latest Developments
13.11 Geropharm
13.11.1 Geropharm Company Information
13.11.2 Geropharm Non-Insulin Hypoglycemic Drug Product Offered
13.11.3 Geropharm Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.11.4 Geropharm Main Business Overview
13.11.5 Geropharm Latest Developments
13.12 Alkem Labs
13.12.1 Alkem Labs Company Information
13.12.2 Alkem Labs Non-Insulin Hypoglycemic Drug Product Offered
13.12.3 Alkem Labs Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.12.4 Alkem Labs Main Business Overview
13.12.5 Alkem Labs Latest Developments
13.13 Jiangsu Hansoh Pharmaceutical
13.13.1 Jiangsu Hansoh Pharmaceutical Company Information
13.13.2 Jiangsu Hansoh Pharmaceutical Non-Insulin Hypoglycemic Drug Product Offered
13.13.3 Jiangsu Hansoh Pharmaceutical Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.13.4 Jiangsu Hansoh Pharmaceutical Main Business Overview
13.13.5 Jiangsu Hansoh Pharmaceutical Latest Developments
13.14 Novo Nordisk
13.14.1 Novo Nordisk Company Information
13.14.2 Novo Nordisk Non-Insulin Hypoglycemic Drug Product Offered
13.14.3 Novo Nordisk Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.14.4 Novo Nordisk Main Business Overview
13.14.5 Novo Nordisk Latest Developments
13.15 Emisphere
13.15.1 Emisphere Company Information
13.15.2 Emisphere Non-Insulin Hypoglycemic Drug Product Offered
13.15.3 Emisphere Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.15.4 Emisphere Main Business Overview
13.15.5 Emisphere Latest Developments
13.16 Uni-Bio Science Group
13.16.1 Uni-Bio Science Group Company Information
13.16.2 Uni-Bio Science Group Non-Insulin Hypoglycemic Drug Product Offered
13.16.3 Uni-Bio Science Group Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.16.4 Uni-Bio Science Group Main Business Overview
13.16.5 Uni-Bio Science Group Latest Developments
13.17 Takeda
13.17.1 Takeda Company Information
13.17.2 Takeda Non-Insulin Hypoglycemic Drug Product Offered
13.17.3 Takeda Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.17.4 Takeda Main Business Overview
13.17.5 Takeda Latest Developments
13.18 3SBio
13.18.1 3SBio Company Information
13.18.2 3SBio Non-Insulin Hypoglycemic Drug Product Offered
13.18.3 3SBio Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.18.4 3SBio Main Business Overview
13.18.5 3SBio Latest Developments
13.19 Jiangsu Hengrui Medicine
13.19.1 Jiangsu Hengrui Medicine Company Information
13.19.2 Jiangsu Hengrui Medicine Non-Insulin Hypoglycemic Drug Product Offered
13.19.3 Jiangsu Hengrui Medicine Non-Insulin Hypoglycemic Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.19.4 Jiangsu Hengrui Medicine Main Business Overview
13.19.5 Jiangsu Hengrui Medicine Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Non-Insulin Hypoglycemic Drug Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. Non-Insulin Hypoglycemic Drug Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of Sulfonylureas
Table 4. Major Players of Meglitinides
Table 5. Major Players of Biguanides
Table 6. Major Players of Thiazolidinediones
Table 7. Major Players of Alpha Glucosidase Inhibitors
Table 8. Major Players of Others
Table 9. Global Non-Insulin Hypoglycemic Drug Sales by Type (2017-2022) & (K Units)
Table 10. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Type (2017-2022)
Table 11. Global Non-Insulin Hypoglycemic Drug Revenue by Type (2017-2022) & ($ million)
Table 12. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Type (2017-2022)
Table 13. Global Non-Insulin Hypoglycemic Drug Sale Price by Type (2017-2022) & (US$/Unit)
Table 14. Global Non-Insulin Hypoglycemic Drug Sales by Application (2017-2022) & (K Units)
Table 15. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Application (2017-2022)
Table 16. Global Non-Insulin Hypoglycemic Drug Revenue by Application (2017-2022)
Table 17. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Application (2017-2022)
Table 18. Global Non-Insulin Hypoglycemic Drug Sale Price by Application (2017-2022) & (US$/Unit)
Table 19. Global Non-Insulin Hypoglycemic Drug Sales by Company (2020-2022) & (K Units)
Table 20. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Company (2020-2022)
Table 21. Global Non-Insulin Hypoglycemic Drug Revenue by Company (2020-2022) ($ Millions)
Table 22. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Company (2020-2022)
Table 23. Global Non-Insulin Hypoglycemic Drug Sale Price by Company (2020-2022) & (US$/Unit)
Table 24. Key Manufacturers Non-Insulin Hypoglycemic Drug Producing Area Distribution and Sales Area
Table 25. Players Non-Insulin Hypoglycemic Drug Products Offered
Table 26. Non-Insulin Hypoglycemic Drug Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 27. New Products and Potential Entrants
Table 28. Mergers & Acquisitions, Expansion
Table 29. Global Non-Insulin Hypoglycemic Drug Sales by Geographic Region (2017-2022) & (K Units)
Table 30. Global Non-Insulin Hypoglycemic Drug Sales Market Share Geographic Region (2017-2022)
Table 31. Global Non-Insulin Hypoglycemic Drug Revenue by Geographic Region (2017-2022) & ($ millions)
Table 32. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Geographic Region (2017-2022)
Table 33. Global Non-Insulin Hypoglycemic Drug Sales by Country/Region (2017-2022) & (K Units)
Table 34. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Country/Region (2017-2022)
Table 35. Global Non-Insulin Hypoglycemic Drug Revenue by Country/Region (2017-2022) & ($ millions)
Table 36. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Country/Region (2017-2022)
Table 37. Americas Non-Insulin Hypoglycemic Drug Sales by Country (2017-2022) & (K Units)
Table 38. Americas Non-Insulin Hypoglycemic Drug Sales Market Share by Country (2017-2022)
Table 39. Americas Non-Insulin Hypoglycemic Drug Revenue by Country (2017-2022) & ($ Millions)
Table 40. Americas Non-Insulin Hypoglycemic Drug Revenue Market Share by Country (2017-2022)
Table 41. Americas Non-Insulin Hypoglycemic Drug Sales by Type (2017-2022) & (K Units)
Table 42. Americas Non-Insulin Hypoglycemic Drug Sales Market Share by Type (2017-2022)
Table 43. Americas Non-Insulin Hypoglycemic Drug Sales by Application (2017-2022) & (K Units)
Table 44. Americas Non-Insulin Hypoglycemic Drug Sales Market Share by Application (2017-2022)
Table 45. APAC Non-Insulin Hypoglycemic Drug Sales by Region (2017-2022) & (K Units)
Table 46. APAC Non-Insulin Hypoglycemic Drug Sales Market Share by Region (2017-2022)
Table 47. APAC Non-Insulin Hypoglycemic Drug Revenue by Region (2017-2022) & ($ Millions)
Table 48. APAC Non-Insulin Hypoglycemic Drug Revenue Market Share by Region (2017-2022)
Table 49. APAC Non-Insulin Hypoglycemic Drug Sales by Type (2017-2022) & (K Units)
Table 50. APAC Non-Insulin Hypoglycemic Drug Sales Market Share by Type (2017-2022)
Table 51. APAC Non-Insulin Hypoglycemic Drug Sales by Application (2017-2022) & (K Units)
Table 52. APAC Non-Insulin Hypoglycemic Drug Sales Market Share by Application (2017-2022)
Table 53. Europe Non-Insulin Hypoglycemic Drug Sales by Country (2017-2022) & (K Units)
Table 54. Europe Non-Insulin Hypoglycemic Drug Sales Market Share by Country (2017-2022)
Table 55. Europe Non-Insulin Hypoglycemic Drug Revenue by Country (2017-2022) & ($ Millions)
Table 56. Europe Non-Insulin Hypoglycemic Drug Revenue Market Share by Country (2017-2022)
Table 57. Europe Non-Insulin Hypoglycemic Drug Sales by Type (2017-2022) & (K Units)
Table 58. Europe Non-Insulin Hypoglycemic Drug Sales Market Share by Type (2017-2022)
Table 59. Europe Non-Insulin Hypoglycemic Drug Sales by Application (2017-2022) & (K Units)
Table 60. Europe Non-Insulin Hypoglycemic Drug Sales Market Share by Application (2017-2022)
Table 61. Middle East & Africa Non-Insulin Hypoglycemic Drug Sales by Country (2017-2022) & (K Units)
Table 62. Middle East & Africa Non-Insulin Hypoglycemic Drug Sales Market Share by Country (2017-2022)
Table 63. Middle East & Africa Non-Insulin Hypoglycemic Drug Revenue by Country (2017-2022) & ($ Millions)
Table 64. Middle East & Africa Non-Insulin Hypoglycemic Drug Revenue Market Share by Country (2017-2022)
Table 65. Middle East & Africa Non-Insulin Hypoglycemic Drug Sales by Type (2017-2022) & (K Units)
Table 66. Middle East & Africa Non-Insulin Hypoglycemic Drug Sales Market Share by Type (2017-2022)
Table 67. Middle East & Africa Non-Insulin Hypoglycemic Drug Sales by Application (2017-2022) & (K Units)
Table 68. Middle East & Africa Non-Insulin Hypoglycemic Drug Sales Market Share by Application (2017-2022)
Table 69. Key Market Drivers & Growth Opportunities of Non-Insulin Hypoglycemic Drug
Table 70. Key Market Challenges & Risks of Non-Insulin Hypoglycemic Drug
Table 71. Key Industry Trends of Non-Insulin Hypoglycemic Drug
Table 72. Non-Insulin Hypoglycemic Drug Raw Material
Table 73. Key Suppliers of Raw Materials
Table 74. Non-Insulin Hypoglycemic Drug Distributors List
Table 75. Non-Insulin Hypoglycemic Drug Customer List
Table 76. Global Non-Insulin Hypoglycemic Drug Sales Forecast by Region (2023-2028) & (K Units)
Table 77. Global Non-Insulin Hypoglycemic Drug Sales Market Forecast by Region
Table 78. Global Non-Insulin Hypoglycemic Drug Revenue Forecast by Region (2023-2028) & ($ millions)
Table 79. Global Non-Insulin Hypoglycemic Drug Revenue Market Share Forecast by Region (2023-2028)
Table 80. Americas Non-Insulin Hypoglycemic Drug Sales Forecast by Country (2023-2028) & (K Units)
Table 81. Americas Non-Insulin Hypoglycemic Drug Revenue Forecast by Country (2023-2028) & ($ millions)
Table 82. APAC Non-Insulin Hypoglycemic Drug Sales Forecast by Region (2023-2028) & (K Units)
Table 83. APAC Non-Insulin Hypoglycemic Drug Revenue Forecast by Region (2023-2028) & ($ millions)
Table 84. Europe Non-Insulin Hypoglycemic Drug Sales Forecast by Country (2023-2028) & (K Units)
Table 85. Europe Non-Insulin Hypoglycemic Drug Revenue Forecast by Country (2023-2028) & ($ millions)
Table 86. Middle East & Africa Non-Insulin Hypoglycemic Drug Sales Forecast by Country (2023-2028) & (K Units)
Table 87. Middle East & Africa Non-Insulin Hypoglycemic Drug Revenue Forecast by Country (2023-2028) & ($ millions)
Table 88. Global Non-Insulin Hypoglycemic Drug Sales Forecast by Type (2023-2028) & (K Units)
Table 89. Global Non-Insulin Hypoglycemic Drug Sales Market Share Forecast by Type (2023-2028)
Table 90. Global Non-Insulin Hypoglycemic Drug Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 91. Global Non-Insulin Hypoglycemic Drug Revenue Market Share Forecast by Type (2023-2028)
Table 92. Global Non-Insulin Hypoglycemic Drug Sales Forecast by Application (2023-2028) & (K Units)
Table 93. Global Non-Insulin Hypoglycemic Drug Sales Market Share Forecast by Application (2023-2028)
Table 94. Global Non-Insulin Hypoglycemic Drug Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 95. Global Non-Insulin Hypoglycemic Drug Revenue Market Share Forecast by Application (2023-2028)
Table 96. GSK Basic Information, Non-Insulin Hypoglycemic Drug Manufacturing Base, Sales Area and Its Competitors
Table 97. GSK Non-Insulin Hypoglycemic Drug Product Offered
Table 98. GSK Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 99. GSK Main Business
Table 100. GSK Latest Developments
Table 101. Eli Lilly Basic Information, Non-Insulin Hypoglycemic Drug Manufacturing Base, Sales Area and Its Competitors
Table 102. Eli Lilly Non-Insulin Hypoglycemic Drug Product Offered
Table 103. Eli Lilly Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 104. Eli Lilly Main Business
Table 105. Eli Lilly Latest Developments
Table 106. Sumitomo Dainippon Pharma Basic Information, Non-Insulin Hypoglycemic Drug Manufacturing Base, Sales Area and Its Competitors
Table 107. Sumitomo Dainippon Pharma Non-Insulin Hypoglycemic Drug Product Offered
Table 108. Sumitomo Dainippon Pharma Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 109. Sumitomo Dainippon Pharma Main Business
Table 110. Sumitomo Dainippon Pharma Latest Developments
Table 111. Intarcia Therapeutics Basic Information, Non-Insulin Hypoglycemic Drug Manufacturing Base, Sales Area and Its Competitors
Table 112. Intarcia Therapeutics Non-Insulin Hypoglycemic Drug Product Offered
Table 113. Intarcia Therapeutics Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 114. Intarcia Therapeutics Main Business
Table 115. Intarcia Therapeutics Latest Developments
Table 116. Servier Basic Information, Non-Insulin Hypoglycemic Drug Manufacturing Base, Sales Area and Its Competitors
Table 117. Servier Non-Insulin Hypoglycemic Drug Product Offered
Table 118. Servier Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 119. Servier Main Business
Table 120. Servier Latest Developments
Table 121. Pfizer Basic Information, Non-Insulin Hypoglycemic Drug Manufacturing Base, Sales Area and Its Competitors
Table 122. Pfizer Non-Insulin Hypoglycemic Drug Product Offered
Table 123. Pfizer Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 124. Pfizer Main Business
Table 125. Pfizer Latest Developments
Table 126. Merck Basic Information, Non-Insulin Hypoglycemic Drug Manufacturing Base, Sales Area and Its Competitors
Table 127. Merck Non-Insulin Hypoglycemic Drug Product Offered
Table 128. Merck Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 129. Merck Main Business
Table 130. Merck Latest Developments
Table 131. Dong-A Pharmaceutical Basic Information, Non-Insulin Hypoglycemic Drug Manufacturing Base, Sales Area and Its Competitors
Table 132. Dong-A Pharmaceutical Non-Insulin Hypoglycemic Drug Product Offered
Table 133. Dong-A Pharmaceutical Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 134. Dong-A Pharmaceutical Main Business
Table 135. Dong-A Pharmaceutical Latest Developments
Table 136. Luye Pharma Group Basic Information, Non-Insulin Hypoglycemic Drug Manufacturing Base, Sales Area and Its Competitors
Table 137. Luye Pharma Group Non-Insulin Hypoglycemic Drug Product Offered
Table 138. Luye Pharma Group Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 139. Luye Pharma Group Main Business
Table 140. Luye Pharma Group Latest Developments
Table 141. Eurofarma Basic Information, Non-Insulin Hypoglycemic Drug Manufacturing Base, Sales Area and Its Competitors
Table 142. Eurofarma Non-Insulin Hypoglycemic Drug Product Offered
Table 143. Eurofarma Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 144. Eurofarma Main Business
Table 145. Eurofarma Latest Developments
Table 146. Geropharm Basic Information, Non-Insulin Hypoglycemic Drug Manufacturing Base, Sales Area and Its Competitors
Table 147. Geropharm Non-Insulin Hypoglycemic Drug Product Offered
Table 148. Geropharm Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 149. Geropharm Main Business
Table 150. Geropharm Latest Developments
Table 151. Alkem Labs Basic Information, Non-Insulin Hypoglycemic Drug Manufacturing Base, Sales Area and Its Competitors
Table 152. Alkem Labs Non-Insulin Hypoglycemic Drug Product Offered
Table 153. Alkem Labs Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 154. Alkem Labs Main Business
Table 155. Alkem Labs Latest Developments
Table 156. Jiangsu Hansoh Pharmaceutical Basic Information, Non-Insulin Hypoglycemic Drug Manufacturing Base, Sales Area and Its Competitors
Table 157. Jiangsu Hansoh Pharmaceutical Non-Insulin Hypoglycemic Drug Product Offered
Table 158. Jiangsu Hansoh Pharmaceutical Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 159. Jiangsu Hansoh Pharmaceutical Main Business
Table 160. Jiangsu Hansoh Pharmaceutical Latest Developments
Table 161. Novo Nordisk Basic Information, Non-Insulin Hypoglycemic Drug Manufacturing Base, Sales Area and Its Competitors
Table 162. Novo Nordisk Non-Insulin Hypoglycemic Drug Product Offered
Table 163. Novo Nordisk Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 164. Novo Nordisk Main Business
Table 165. Novo Nordisk Latest Developments
Table 166. Emisphere Basic Information, Non-Insulin Hypoglycemic Drug Manufacturing Base, Sales Area and Its Competitors
Table 167. Emisphere Non-Insulin Hypoglycemic Drug Product Offered
Table 168. Emisphere Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 169. Emisphere Main Business
Table 170. Emisphere Latest Developments
Table 171. Uni-Bio Science Group Basic Information, Non-Insulin Hypoglycemic Drug Manufacturing Base, Sales Area and Its Competitors
Table 172. Uni-Bio Science Group Non-Insulin Hypoglycemic Drug Product Offered
Table 173. Uni-Bio Science Group Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 174. Uni-Bio Science Group Main Business
Table 175. Uni-Bio Science Group Latest Developments
Table 176. Takeda Basic Information, Non-Insulin Hypoglycemic Drug Manufacturing Base, Sales Area and Its Competitors
Table 177. Takeda Non-Insulin Hypoglycemic Drug Product Offered
Table 178. Takeda Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 179. Takeda Main Business
Table 180. Takeda Latest Developments
Table 181. 3SBio Basic Information, Non-Insulin Hypoglycemic Drug Manufacturing Base, Sales Area and Its Competitors
Table 182. 3SBio Non-Insulin Hypoglycemic Drug Product Offered
Table 183. 3SBio Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 184. 3SBio Main Business
Table 185. 3SBio Latest Developments
Table 186. Jiangsu Hengrui Medicine Basic Information, Non-Insulin Hypoglycemic Drug Manufacturing Base, Sales Area and Its Competitors
Table 187. Jiangsu Hengrui Medicine Non-Insulin Hypoglycemic Drug Product Offered
Table 188. Jiangsu Hengrui Medicine Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 189. Jiangsu Hengrui Medicine Main Business
Table 190. Jiangsu Hengrui Medicine Latest Developments
Table 1. Non-Insulin Hypoglycemic Drug Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. Non-Insulin Hypoglycemic Drug Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of Sulfonylureas
Table 4. Major Players of Meglitinides
Table 5. Major Players of Biguanides
Table 6. Major Players of Thiazolidinediones
Table 7. Major Players of Alpha Glucosidase Inhibitors
Table 8. Major Players of Others
Table 9. Global Non-Insulin Hypoglycemic Drug Sales by Type (2017-2022) & (K Units)
Table 10. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Type (2017-2022)
Table 11. Global Non-Insulin Hypoglycemic Drug Revenue by Type (2017-2022) & ($ million)
Table 12. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Type (2017-2022)
Table 13. Global Non-Insulin Hypoglycemic Drug Sale Price by Type (2017-2022) & (US$/Unit)
Table 14. Global Non-Insulin Hypoglycemic Drug Sales by Application (2017-2022) & (K Units)
Table 15. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Application (2017-2022)
Table 16. Global Non-Insulin Hypoglycemic Drug Revenue by Application (2017-2022)
Table 17. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Application (2017-2022)
Table 18. Global Non-Insulin Hypoglycemic Drug Sale Price by Application (2017-2022) & (US$/Unit)
Table 19. Global Non-Insulin Hypoglycemic Drug Sales by Company (2020-2022) & (K Units)
Table 20. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Company (2020-2022)
Table 21. Global Non-Insulin Hypoglycemic Drug Revenue by Company (2020-2022) ($ Millions)
Table 22. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Company (2020-2022)
Table 23. Global Non-Insulin Hypoglycemic Drug Sale Price by Company (2020-2022) & (US$/Unit)
Table 24. Key Manufacturers Non-Insulin Hypoglycemic Drug Producing Area Distribution and Sales Area
Table 25. Players Non-Insulin Hypoglycemic Drug Products Offered
Table 26. Non-Insulin Hypoglycemic Drug Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 27. New Products and Potential Entrants
Table 28. Mergers & Acquisitions, Expansion
Table 29. Global Non-Insulin Hypoglycemic Drug Sales by Geographic Region (2017-2022) & (K Units)
Table 30. Global Non-Insulin Hypoglycemic Drug Sales Market Share Geographic Region (2017-2022)
Table 31. Global Non-Insulin Hypoglycemic Drug Revenue by Geographic Region (2017-2022) & ($ millions)
Table 32. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Geographic Region (2017-2022)
Table 33. Global Non-Insulin Hypoglycemic Drug Sales by Country/Region (2017-2022) & (K Units)
Table 34. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Country/Region (2017-2022)
Table 35. Global Non-Insulin Hypoglycemic Drug Revenue by Country/Region (2017-2022) & ($ millions)
Table 36. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Country/Region (2017-2022)
Table 37. Americas Non-Insulin Hypoglycemic Drug Sales by Country (2017-2022) & (K Units)
Table 38. Americas Non-Insulin Hypoglycemic Drug Sales Market Share by Country (2017-2022)
Table 39. Americas Non-Insulin Hypoglycemic Drug Revenue by Country (2017-2022) & ($ Millions)
Table 40. Americas Non-Insulin Hypoglycemic Drug Revenue Market Share by Country (2017-2022)
Table 41. Americas Non-Insulin Hypoglycemic Drug Sales by Type (2017-2022) & (K Units)
Table 42. Americas Non-Insulin Hypoglycemic Drug Sales Market Share by Type (2017-2022)
Table 43. Americas Non-Insulin Hypoglycemic Drug Sales by Application (2017-2022) & (K Units)
Table 44. Americas Non-Insulin Hypoglycemic Drug Sales Market Share by Application (2017-2022)
Table 45. APAC Non-Insulin Hypoglycemic Drug Sales by Region (2017-2022) & (K Units)
Table 46. APAC Non-Insulin Hypoglycemic Drug Sales Market Share by Region (2017-2022)
Table 47. APAC Non-Insulin Hypoglycemic Drug Revenue by Region (2017-2022) & ($ Millions)
Table 48. APAC Non-Insulin Hypoglycemic Drug Revenue Market Share by Region (2017-2022)
Table 49. APAC Non-Insulin Hypoglycemic Drug Sales by Type (2017-2022) & (K Units)
Table 50. APAC Non-Insulin Hypoglycemic Drug Sales Market Share by Type (2017-2022)
Table 51. APAC Non-Insulin Hypoglycemic Drug Sales by Application (2017-2022) & (K Units)
Table 52. APAC Non-Insulin Hypoglycemic Drug Sales Market Share by Application (2017-2022)
Table 53. Europe Non-Insulin Hypoglycemic Drug Sales by Country (2017-2022) & (K Units)
Table 54. Europe Non-Insulin Hypoglycemic Drug Sales Market Share by Country (2017-2022)
Table 55. Europe Non-Insulin Hypoglycemic Drug Revenue by Country (2017-2022) & ($ Millions)
Table 56. Europe Non-Insulin Hypoglycemic Drug Revenue Market Share by Country (2017-2022)
Table 57. Europe Non-Insulin Hypoglycemic Drug Sales by Type (2017-2022) & (K Units)
Table 58. Europe Non-Insulin Hypoglycemic Drug Sales Market Share by Type (2017-2022)
Table 59. Europe Non-Insulin Hypoglycemic Drug Sales by Application (2017-2022) & (K Units)
Table 60. Europe Non-Insulin Hypoglycemic Drug Sales Market Share by Application (2017-2022)
Table 61. Middle East & Africa Non-Insulin Hypoglycemic Drug Sales by Country (2017-2022) & (K Units)
Table 62. Middle East & Africa Non-Insulin Hypoglycemic Drug Sales Market Share by Country (2017-2022)
Table 63. Middle East & Africa Non-Insulin Hypoglycemic Drug Revenue by Country (2017-2022) & ($ Millions)
Table 64. Middle East & Africa Non-Insulin Hypoglycemic Drug Revenue Market Share by Country (2017-2022)
Table 65. Middle East & Africa Non-Insulin Hypoglycemic Drug Sales by Type (2017-2022) & (K Units)
Table 66. Middle East & Africa Non-Insulin Hypoglycemic Drug Sales Market Share by Type (2017-2022)
Table 67. Middle East & Africa Non-Insulin Hypoglycemic Drug Sales by Application (2017-2022) & (K Units)
Table 68. Middle East & Africa Non-Insulin Hypoglycemic Drug Sales Market Share by Application (2017-2022)
Table 69. Key Market Drivers & Growth Opportunities of Non-Insulin Hypoglycemic Drug
Table 70. Key Market Challenges & Risks of Non-Insulin Hypoglycemic Drug
Table 71. Key Industry Trends of Non-Insulin Hypoglycemic Drug
Table 72. Non-Insulin Hypoglycemic Drug Raw Material
Table 73. Key Suppliers of Raw Materials
Table 74. Non-Insulin Hypoglycemic Drug Distributors List
Table 75. Non-Insulin Hypoglycemic Drug Customer List
Table 76. Global Non-Insulin Hypoglycemic Drug Sales Forecast by Region (2023-2028) & (K Units)
Table 77. Global Non-Insulin Hypoglycemic Drug Sales Market Forecast by Region
Table 78. Global Non-Insulin Hypoglycemic Drug Revenue Forecast by Region (2023-2028) & ($ millions)
Table 79. Global Non-Insulin Hypoglycemic Drug Revenue Market Share Forecast by Region (2023-2028)
Table 80. Americas Non-Insulin Hypoglycemic Drug Sales Forecast by Country (2023-2028) & (K Units)
Table 81. Americas Non-Insulin Hypoglycemic Drug Revenue Forecast by Country (2023-2028) & ($ millions)
Table 82. APAC Non-Insulin Hypoglycemic Drug Sales Forecast by Region (2023-2028) & (K Units)
Table 83. APAC Non-Insulin Hypoglycemic Drug Revenue Forecast by Region (2023-2028) & ($ millions)
Table 84. Europe Non-Insulin Hypoglycemic Drug Sales Forecast by Country (2023-2028) & (K Units)
Table 85. Europe Non-Insulin Hypoglycemic Drug Revenue Forecast by Country (2023-2028) & ($ millions)
Table 86. Middle East & Africa Non-Insulin Hypoglycemic Drug Sales Forecast by Country (2023-2028) & (K Units)
Table 87. Middle East & Africa Non-Insulin Hypoglycemic Drug Revenue Forecast by Country (2023-2028) & ($ millions)
Table 88. Global Non-Insulin Hypoglycemic Drug Sales Forecast by Type (2023-2028) & (K Units)
Table 89. Global Non-Insulin Hypoglycemic Drug Sales Market Share Forecast by Type (2023-2028)
Table 90. Global Non-Insulin Hypoglycemic Drug Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 91. Global Non-Insulin Hypoglycemic Drug Revenue Market Share Forecast by Type (2023-2028)
Table 92. Global Non-Insulin Hypoglycemic Drug Sales Forecast by Application (2023-2028) & (K Units)
Table 93. Global Non-Insulin Hypoglycemic Drug Sales Market Share Forecast by Application (2023-2028)
Table 94. Global Non-Insulin Hypoglycemic Drug Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 95. Global Non-Insulin Hypoglycemic Drug Revenue Market Share Forecast by Application (2023-2028)
Table 96. GSK Basic Information, Non-Insulin Hypoglycemic Drug Manufacturing Base, Sales Area and Its Competitors
Table 97. GSK Non-Insulin Hypoglycemic Drug Product Offered
Table 98. GSK Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 99. GSK Main Business
Table 100. GSK Latest Developments
Table 101. Eli Lilly Basic Information, Non-Insulin Hypoglycemic Drug Manufacturing Base, Sales Area and Its Competitors
Table 102. Eli Lilly Non-Insulin Hypoglycemic Drug Product Offered
Table 103. Eli Lilly Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 104. Eli Lilly Main Business
Table 105. Eli Lilly Latest Developments
Table 106. Sumitomo Dainippon Pharma Basic Information, Non-Insulin Hypoglycemic Drug Manufacturing Base, Sales Area and Its Competitors
Table 107. Sumitomo Dainippon Pharma Non-Insulin Hypoglycemic Drug Product Offered
Table 108. Sumitomo Dainippon Pharma Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 109. Sumitomo Dainippon Pharma Main Business
Table 110. Sumitomo Dainippon Pharma Latest Developments
Table 111. Intarcia Therapeutics Basic Information, Non-Insulin Hypoglycemic Drug Manufacturing Base, Sales Area and Its Competitors
Table 112. Intarcia Therapeutics Non-Insulin Hypoglycemic Drug Product Offered
Table 113. Intarcia Therapeutics Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 114. Intarcia Therapeutics Main Business
Table 115. Intarcia Therapeutics Latest Developments
Table 116. Servier Basic Information, Non-Insulin Hypoglycemic Drug Manufacturing Base, Sales Area and Its Competitors
Table 117. Servier Non-Insulin Hypoglycemic Drug Product Offered
Table 118. Servier Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 119. Servier Main Business
Table 120. Servier Latest Developments
Table 121. Pfizer Basic Information, Non-Insulin Hypoglycemic Drug Manufacturing Base, Sales Area and Its Competitors
Table 122. Pfizer Non-Insulin Hypoglycemic Drug Product Offered
Table 123. Pfizer Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 124. Pfizer Main Business
Table 125. Pfizer Latest Developments
Table 126. Merck Basic Information, Non-Insulin Hypoglycemic Drug Manufacturing Base, Sales Area and Its Competitors
Table 127. Merck Non-Insulin Hypoglycemic Drug Product Offered
Table 128. Merck Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 129. Merck Main Business
Table 130. Merck Latest Developments
Table 131. Dong-A Pharmaceutical Basic Information, Non-Insulin Hypoglycemic Drug Manufacturing Base, Sales Area and Its Competitors
Table 132. Dong-A Pharmaceutical Non-Insulin Hypoglycemic Drug Product Offered
Table 133. Dong-A Pharmaceutical Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 134. Dong-A Pharmaceutical Main Business
Table 135. Dong-A Pharmaceutical Latest Developments
Table 136. Luye Pharma Group Basic Information, Non-Insulin Hypoglycemic Drug Manufacturing Base, Sales Area and Its Competitors
Table 137. Luye Pharma Group Non-Insulin Hypoglycemic Drug Product Offered
Table 138. Luye Pharma Group Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 139. Luye Pharma Group Main Business
Table 140. Luye Pharma Group Latest Developments
Table 141. Eurofarma Basic Information, Non-Insulin Hypoglycemic Drug Manufacturing Base, Sales Area and Its Competitors
Table 142. Eurofarma Non-Insulin Hypoglycemic Drug Product Offered
Table 143. Eurofarma Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 144. Eurofarma Main Business
Table 145. Eurofarma Latest Developments
Table 146. Geropharm Basic Information, Non-Insulin Hypoglycemic Drug Manufacturing Base, Sales Area and Its Competitors
Table 147. Geropharm Non-Insulin Hypoglycemic Drug Product Offered
Table 148. Geropharm Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 149. Geropharm Main Business
Table 150. Geropharm Latest Developments
Table 151. Alkem Labs Basic Information, Non-Insulin Hypoglycemic Drug Manufacturing Base, Sales Area and Its Competitors
Table 152. Alkem Labs Non-Insulin Hypoglycemic Drug Product Offered
Table 153. Alkem Labs Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 154. Alkem Labs Main Business
Table 155. Alkem Labs Latest Developments
Table 156. Jiangsu Hansoh Pharmaceutical Basic Information, Non-Insulin Hypoglycemic Drug Manufacturing Base, Sales Area and Its Competitors
Table 157. Jiangsu Hansoh Pharmaceutical Non-Insulin Hypoglycemic Drug Product Offered
Table 158. Jiangsu Hansoh Pharmaceutical Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 159. Jiangsu Hansoh Pharmaceutical Main Business
Table 160. Jiangsu Hansoh Pharmaceutical Latest Developments
Table 161. Novo Nordisk Basic Information, Non-Insulin Hypoglycemic Drug Manufacturing Base, Sales Area and Its Competitors
Table 162. Novo Nordisk Non-Insulin Hypoglycemic Drug Product Offered
Table 163. Novo Nordisk Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 164. Novo Nordisk Main Business
Table 165. Novo Nordisk Latest Developments
Table 166. Emisphere Basic Information, Non-Insulin Hypoglycemic Drug Manufacturing Base, Sales Area and Its Competitors
Table 167. Emisphere Non-Insulin Hypoglycemic Drug Product Offered
Table 168. Emisphere Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 169. Emisphere Main Business
Table 170. Emisphere Latest Developments
Table 171. Uni-Bio Science Group Basic Information, Non-Insulin Hypoglycemic Drug Manufacturing Base, Sales Area and Its Competitors
Table 172. Uni-Bio Science Group Non-Insulin Hypoglycemic Drug Product Offered
Table 173. Uni-Bio Science Group Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 174. Uni-Bio Science Group Main Business
Table 175. Uni-Bio Science Group Latest Developments
Table 176. Takeda Basic Information, Non-Insulin Hypoglycemic Drug Manufacturing Base, Sales Area and Its Competitors
Table 177. Takeda Non-Insulin Hypoglycemic Drug Product Offered
Table 178. Takeda Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 179. Takeda Main Business
Table 180. Takeda Latest Developments
Table 181. 3SBio Basic Information, Non-Insulin Hypoglycemic Drug Manufacturing Base, Sales Area and Its Competitors
Table 182. 3SBio Non-Insulin Hypoglycemic Drug Product Offered
Table 183. 3SBio Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 184. 3SBio Main Business
Table 185. 3SBio Latest Developments
Table 186. Jiangsu Hengrui Medicine Basic Information, Non-Insulin Hypoglycemic Drug Manufacturing Base, Sales Area and Its Competitors
Table 187. Jiangsu Hengrui Medicine Non-Insulin Hypoglycemic Drug Product Offered
Table 188. Jiangsu Hengrui Medicine Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 189. Jiangsu Hengrui Medicine Main Business
Table 190. Jiangsu Hengrui Medicine Latest Developments
LIST OF FIGURES
Figure 1. Picture of Non-Insulin Hypoglycemic Drug
Figure 2. Non-Insulin Hypoglycemic Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Non-Insulin Hypoglycemic Drug Sales Growth Rate 2017-2028 (K Units)
Figure 7. Global Non-Insulin Hypoglycemic Drug Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. Non-Insulin Hypoglycemic Drug Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of Sulfonylureas
Figure 10. Product Picture of Meglitinides
Figure 11. Product Picture of Biguanides
Figure 12. Product Picture of Thiazolidinediones
Figure 13. Product Picture of Alpha Glucosidase Inhibitors
Figure 14. Product Picture of Others
Figure 15. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Type in 2021
Figure 16. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Type (2017-2022)
Figure 17. Non-Insulin Hypoglycemic Drug Consumed in Hospital Pharmacies
Figure 18. Global Non-Insulin Hypoglycemic Drug Market: Hospital Pharmacies (2017-2022) & (K Units)
Figure 19. Non-Insulin Hypoglycemic Drug Consumed in Retail Pharmacies
Figure 20. Global Non-Insulin Hypoglycemic Drug Market: Retail Pharmacies (2017-2022) & (K Units)
Figure 21. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Application (2017-2022)
Figure 22. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Application in 2021
Figure 23. Non-Insulin Hypoglycemic Drug Revenue Market by Company in 2021 ($ Million)
Figure 24. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Company in 2021
Figure 25. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Geographic Region (2017-2022)
Figure 26. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Geographic Region in 2021
Figure 27. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Region (2017-2022)
Figure 28. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Country/Region in 2021
Figure 29. Americas Non-Insulin Hypoglycemic Drug Sales 2017-2022 (K Units)
Figure 30. Americas Non-Insulin Hypoglycemic Drug Revenue 2017-2022 ($ Millions)
Figure 31. APAC Non-Insulin Hypoglycemic Drug Sales 2017-2022 (K Units)
Figure 32. APAC Non-Insulin Hypoglycemic Drug Revenue 2017-2022 ($ Millions)
Figure 33. Europe Non-Insulin Hypoglycemic Drug Sales 2017-2022 (K Units)
Figure 34. Europe Non-Insulin Hypoglycemic Drug Revenue 2017-2022 ($ Millions)
Figure 35. Middle East & Africa Non-Insulin Hypoglycemic Drug Sales 2017-2022 (K Units)
Figure 36. Middle East & Africa Non-Insulin Hypoglycemic Drug Revenue 2017-2022 ($ Millions)
Figure 37. Americas Non-Insulin Hypoglycemic Drug Sales Market Share by Country in 2021
Figure 38. Americas Non-Insulin Hypoglycemic Drug Revenue Market Share by Country in 2021
Figure 39. United States Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 ($ Millions)
Figure 40. Canada Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 ($ Millions)
Figure 41. Mexico Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 ($ Millions)
Figure 42. Brazil Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 ($ Millions)
Figure 43. APAC Non-Insulin Hypoglycemic Drug Sales Market Share by Region in 2021
Figure 44. APAC Non-Insulin Hypoglycemic Drug Revenue Market Share by Regions in 2021
Figure 45. China Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 ($ Millions)
Figure 46. Japan Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 ($ Millions)
Figure 47. South Korea Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 ($ Millions)
Figure 48. Southeast Asia Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 ($ Millions)
Figure 49. India Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 ($ Millions)
Figure 50. Australia Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 ($ Millions)
Figure 51. Europe Non-Insulin Hypoglycemic Drug Sales Market Share by Country in 2021
Figure 52. Europe Non-Insulin Hypoglycemic Drug Revenue Market Share by Country in 2021
Figure 53. Germany Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 ($ Millions)
Figure 54. France Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 ($ Millions)
Figure 55. UK Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 ($ Millions)
Figure 56. Italy Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 ($ Millions)
Figure 57. Russia Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 ($ Millions)
Figure 58. Middle East & Africa Non-Insulin Hypoglycemic Drug Sales Market Share by Country in 2021
Figure 59. Middle East & Africa Non-Insulin Hypoglycemic Drug Revenue Market Share by Country in 2021
Figure 60. Egypt Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 ($ Millions)
Figure 61. South Africa Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 ($ Millions)
Figure 62. Israel Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 ($ Millions)
Figure 63. Turkey Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 ($ Millions)
Figure 64. GCC Country Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 ($ Millions)
Figure 65. Manufacturing Cost Structure Analysis of Non-Insulin Hypoglycemic Drug in 2021
Figure 66. Manufacturing Process Analysis of Non-Insulin Hypoglycemic Drug
Figure 67. Industry Chain Structure of Non-Insulin Hypoglycemic Drug
Figure 68. Channels of Distribution
Figure 69. Distributors Profiles
Figure 1. Picture of Non-Insulin Hypoglycemic Drug
Figure 2. Non-Insulin Hypoglycemic Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Non-Insulin Hypoglycemic Drug Sales Growth Rate 2017-2028 (K Units)
Figure 7. Global Non-Insulin Hypoglycemic Drug Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. Non-Insulin Hypoglycemic Drug Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of Sulfonylureas
Figure 10. Product Picture of Meglitinides
Figure 11. Product Picture of Biguanides
Figure 12. Product Picture of Thiazolidinediones
Figure 13. Product Picture of Alpha Glucosidase Inhibitors
Figure 14. Product Picture of Others
Figure 15. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Type in 2021
Figure 16. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Type (2017-2022)
Figure 17. Non-Insulin Hypoglycemic Drug Consumed in Hospital Pharmacies
Figure 18. Global Non-Insulin Hypoglycemic Drug Market: Hospital Pharmacies (2017-2022) & (K Units)
Figure 19. Non-Insulin Hypoglycemic Drug Consumed in Retail Pharmacies
Figure 20. Global Non-Insulin Hypoglycemic Drug Market: Retail Pharmacies (2017-2022) & (K Units)
Figure 21. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Application (2017-2022)
Figure 22. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Application in 2021
Figure 23. Non-Insulin Hypoglycemic Drug Revenue Market by Company in 2021 ($ Million)
Figure 24. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Company in 2021
Figure 25. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Geographic Region (2017-2022)
Figure 26. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Geographic Region in 2021
Figure 27. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Region (2017-2022)
Figure 28. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Country/Region in 2021
Figure 29. Americas Non-Insulin Hypoglycemic Drug Sales 2017-2022 (K Units)
Figure 30. Americas Non-Insulin Hypoglycemic Drug Revenue 2017-2022 ($ Millions)
Figure 31. APAC Non-Insulin Hypoglycemic Drug Sales 2017-2022 (K Units)
Figure 32. APAC Non-Insulin Hypoglycemic Drug Revenue 2017-2022 ($ Millions)
Figure 33. Europe Non-Insulin Hypoglycemic Drug Sales 2017-2022 (K Units)
Figure 34. Europe Non-Insulin Hypoglycemic Drug Revenue 2017-2022 ($ Millions)
Figure 35. Middle East & Africa Non-Insulin Hypoglycemic Drug Sales 2017-2022 (K Units)
Figure 36. Middle East & Africa Non-Insulin Hypoglycemic Drug Revenue 2017-2022 ($ Millions)
Figure 37. Americas Non-Insulin Hypoglycemic Drug Sales Market Share by Country in 2021
Figure 38. Americas Non-Insulin Hypoglycemic Drug Revenue Market Share by Country in 2021
Figure 39. United States Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 ($ Millions)
Figure 40. Canada Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 ($ Millions)
Figure 41. Mexico Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 ($ Millions)
Figure 42. Brazil Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 ($ Millions)
Figure 43. APAC Non-Insulin Hypoglycemic Drug Sales Market Share by Region in 2021
Figure 44. APAC Non-Insulin Hypoglycemic Drug Revenue Market Share by Regions in 2021
Figure 45. China Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 ($ Millions)
Figure 46. Japan Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 ($ Millions)
Figure 47. South Korea Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 ($ Millions)
Figure 48. Southeast Asia Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 ($ Millions)
Figure 49. India Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 ($ Millions)
Figure 50. Australia Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 ($ Millions)
Figure 51. Europe Non-Insulin Hypoglycemic Drug Sales Market Share by Country in 2021
Figure 52. Europe Non-Insulin Hypoglycemic Drug Revenue Market Share by Country in 2021
Figure 53. Germany Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 ($ Millions)
Figure 54. France Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 ($ Millions)
Figure 55. UK Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 ($ Millions)
Figure 56. Italy Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 ($ Millions)
Figure 57. Russia Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 ($ Millions)
Figure 58. Middle East & Africa Non-Insulin Hypoglycemic Drug Sales Market Share by Country in 2021
Figure 59. Middle East & Africa Non-Insulin Hypoglycemic Drug Revenue Market Share by Country in 2021
Figure 60. Egypt Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 ($ Millions)
Figure 61. South Africa Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 ($ Millions)
Figure 62. Israel Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 ($ Millions)
Figure 63. Turkey Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 ($ Millions)
Figure 64. GCC Country Non-Insulin Hypoglycemic Drug Revenue Growth 2017-2022 ($ Millions)
Figure 65. Manufacturing Cost Structure Analysis of Non-Insulin Hypoglycemic Drug in 2021
Figure 66. Manufacturing Process Analysis of Non-Insulin Hypoglycemic Drug
Figure 67. Industry Chain Structure of Non-Insulin Hypoglycemic Drug
Figure 68. Channels of Distribution
Figure 69. Distributors Profiles
